Stock 600789 SHANDONG LUKANG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shandong Lukang Pharmaceutical Co.,Ltd.

Equities

600789

CNE000000P61

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 20/05/2024 BST 		5-day change 1st Jan Change
8.92 CNY -3.98% Intraday chart for Shandong Lukang Pharmaceutical Co.,Ltd. -15.77% +24.93%
04-23 Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-22 Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Lukang Pharmaceutical Gets Nod to Produce Parkinson's Disease Drug
Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation
Lukang Pharmaceutical's Ampicillin Sodium and Sulbactam Sodium Pass Regulatory Evaluation
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Lukang Pharmaceutical's Ornidazole Tablets Passes Regulatory Evaluation
Lukang Pharma Generic Hypertension Drug Passes Regulatory Evaluation
Lukang Pharmaceutical's Cefaclor Granules Passes Chinese Drug Regulator's Evaluation
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Lukang Pharmaceutical's Cefminox Sodium for Injection Passes Regulatory Evaluation
Lukang Pharmaceutical's Cefaclor Capsules Passes Regulatory Evaluation
Lukang Pharma's Ampicillin Sodium for Injection Passes Regulatory Evaluation
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Lukang Pharma Gets Nod to Market Anti-Arthritis Drug Ingredient
Lukang Pharma’s Benzyl Alcohol Wins Marketing Approval in China
Shandong Lukang Pharmaceutical Raising 1.2 Billion Yuan to Fund Expansion Plans
Lukang Pharma Gets Regulatory Nod for Anti-Pneumonia Drug
Lukang Pharmaceutical Gets Approval for Diabetes Treatment Tablet
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600789 Stock
  4. News Shandong Lukang Pharmaceutical Co.,Ltd.
  5. Other languages